| Record ID | marc_records_scriblio_net/part27.dat:124693586:1145 |
| Source | Scriblio |
| Download Link | /show-records/marc_records_scriblio_net/part27.dat:124693586:1145?format=raw |
LEADER: 01145nam 2200277 a 4500
001 98121716
003 DLC
005 19980602113303.0
008 980303s1996 fr a b 101 0 eng d
010 $a 98121716
020 $a9283212665
035 $a(CStRLIN)NJRG97-B1143
040 $aNjR$cNjR$dDLC
042 $alccopycat
050 00 $aRC268.65$b.I26 1996
082 00 $a615/.7$221
110 2 $aIARC Working Group on the Evaluation of Carcinogenic Risks to Humans.
245 10 $aSome pharmaceutical drugs.
260 $a[Lyon] :$bWorld Health Organization, International Agency for Research on Cancer,$c1996.
300 $aiv, 514 p. :$bill. ;$c25 cm.
440 0 $aIARC monographs on the evaluation of carcinogenic risks to humans ;$vv. 66
500 $a"This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans which met in Lyon, 13-20 February 1996."
504 $aIncludes bibliographical references and index.
650 0 $aDrugs$xPhysiological effect$xCongresses.
650 0 $aCarcinogens$xCongresses.
710 2 $aInternational Agency for Research on Cancer.